Last reviewed · How we verify

NCT04033497

Treatment Response Assessment Maps to Delineate Necrosis From Tumor After Stereotactic Radiation in Brain Metastases

Recruiting now NA Last updated 19 March 2026
What this trial tests

NA trial testing MRI in Brain Tumor in 101 participants. Currently enrolling.

Timeline
20 August 2019
Primary endpoint
1 July 2027
1 July 2028

Quick facts

Lead sponsorBrigham and Women's Hospital
PhaseNA
StatusRecruiting now
Study typeINTERVENTIONAL
Allocationna
Designsingle group
Maskingnone
Primary purposediagnostic
Enrollment101
Start date20 August 2019
Primary completion1 July 2027
Estimated completion1 July 2028
Sites2 locations across United States

Drugs / interventions tested

Conditions studied

Sponsor

Brigham and Women's Hospital

Who can join

18 and older, any sex, with Brain Tumor. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This research study is investigating the value of an imaging study of the brain called an MRI (which stands for magnetic resonance imaging), utilized in unique way, to delineate whether the tumor has recurred or whether radiation changes have occurred after a brain metastasis treated with focused radiation has enlarged.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other trials of MRI

Trials testing the same drug.

Other recruiting trials for Brain Tumor

Currently open trials in the same condition.

Other Brigham and Women's Hospital trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04033497.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing